Invivyd (IVVD) announced that new in vitro neutralization data show continued neutralizing activity of PEMGARDA and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. As anticipated based on the structural biology of pemivibart and VYD2311, the data are largely consistent with those previously reported for KP.3.1.1. The Centers for Disease Control estimates that XEC and KP.3.1.1 accounted for an aggregate 69% of U.S. circulating variants of SARS-CoV-2 for the two weeks ended December 21, 2024. Invivyd generated these new data as part of its ongoing industrial virology effort, which leverages a consistent, high-quality, independent, third-party pseudoviral system that routinely tests authentic Invivyd-produced pemivibart and is supported by extensive structure-based and proprietary analytics.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd price target lowered to $3.55 from $9.50 at Morgan Stanley
- Invivyd price target lowered to $10 from $15 at H.C. Wainwright
- Invivyd’s Q3 2024: Revenue Growth and Strategic Developments
- Invivyd reports Q3 EPS (51c) vs (36c) last year
- Invivyd announces NEJM published letter to editor on PEMGARDA